Shillong Herald

Metastatic Breast Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

 Breaking News
  • No posts were found

Metastatic Breast Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

May 10
19:44 2023
Metastatic Breast Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies,  Mechanism of Action, Route of Administration by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Metastatic Breast Cancer pipeline constitutes 100+ key companies continuously working towards developing 100+ Metastatic Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Metastatic Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Metastatic Breast Cancer Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Breast Cancer Market.

 

Some of the key takeaways from the Metastatic Breast Cancer Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Metastatic Breast Cancer treatment therapies with a considerable amount of success over the years. 
  • Metastatic Breast Cancer companies working in the treatment market are Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S., Jiangsu HengRui Medicine Co., Ltd., Genor Biopharma Co., Ltd, Phoenix Molecular Designs, Dantari, Inc, Daiichi Sankyo Co., Ltd., and others, are developing therapies for the Metastatic Breast Cancer treatment 
  • Emerging Metastatic Breast Cancer therapies such as – Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant , PMD-026, DAN-222, Patritumab Deruxtecan, and others are expected to have a significant impact on the Metastatic Breast Cancer market in the coming years.   
  • In September 2021, A Phase III clinical trial of GB491 and Fulvestrant in patients with HR+, HER2-positive locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy has been started by Genor Biopharma
  • In June 2020, An exclusive licence agreement for the development and commercialization of lerociclib in the Asia-Pacific region (apart from Japan) was announced by G1 Therapeutics, Inc., a clinical-stage oncology company, and Genor Biopharma Co. Inc., a precommercial stage biopharmaceutical company specialising in the development and commercialization of immune-oncology therapeutics

 

Metastatic Breast Cancer Overview

Breast cancer that has migrated to another body site, most frequently the bones, lungs, brain, or liver, is referred to as metastatic breast cancer, also known as stage IV. Even after the initial diagnosis and treatment, breast cancer can return in another area of the body months or even years later. This is referred to as a distant or metastatic recurrence.

 

Get a Free Sample PDF Report to know more about Metastatic Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/metastatic-breast-cancer-pipeline-insight

 

Emerging Metastatic Breast Cancer Drugs Under Different Phases of Clinical Development Include:

  • PMD-026: Phoenix Molecular Designs
  • DAN-222: Dantari, Inc
  • Giredestrant: Roche
  • Disitamab Vedotin: RemeGen
  • EndoTAG®-1 (SB05): SynCore Biotechnology
  • Stenoparib (2X-121): Allarity Therapeutics
  • Patritumab Deruxtecan: Daiichi Sankyo Co., Ltd.
  • Tenalisib: Rhizen Pharmaceuticals SA
  • OP-1250: Olema Oncology
  • Eftilagimod alpha: Immutep S.A.S.
  • SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
  • GB491+ Fulvestrant : Genor Biopharma Co., Ltd

 

Route of Administration

Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Metastatic Breast Cancer Pipeline Therapeutics Assessment

  • Metastatic Breast Cancer Assessment by Product Type
  • Metastatic Breast Cancer By Stage and Product Type
  • Metastatic Breast Cancer Assessment by Route of Administration
  • Metastatic Breast Cancer By Stage and Route of Administration
  • Metastatic Breast Cancer Assessment by Molecule Type
  • Metastatic Breast Cancer by Stage and Molecule Type

 

DelveInsight’s Metastatic Breast Cancer Report covers around 100+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Metastatic Breast Cancer product details are provided in the report. Download the Metastatic Breast Cancer pipeline report to learn more about the emerging Metastatic Breast Cancer therapies

 

Some of the key companies in the Metastatic Breast Cancer Therapeutics Market include:

Key companies developing therapies for Metastatic Breast Cancer are – Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd.,  Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., and others.

 

Metastatic Breast Cancer Pipeline Analysis:

The Metastatic Breast Cancer pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Breast Cancer Treatment.
  • Metastatic Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Metastatic Breast Cancer drugs and therapies

 

Metastatic Breast Cancer Pipeline Market Drivers

  • Increasing prevalence of breast cancer, launch of several diagnostic and screening programs are some of the important factors that are fueling the Metastatic Breast Cancer Market.

 

Metastatic Breast Cancer Pipeline Market Barriers

  • However, high cost associated with the treatment, several side effects associated with the use of breast cancer therapeutics and other factors are creating obstacles in the Metastatic Breast Cancer Market growth.

 

Scope of Metastatic Breast Cancer Pipeline Drug Insight    

  • Coverage: Global
  • Key Metastatic Breast Cancer Companies: Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S., Jiangsu HengRui Medicine Co., Ltd., Genor Biopharma Co., Ltd, Phoenix Molecular Designs, Dantari, Inc, Daiichi Sankyo Co., Ltd., and others
  • Key Metastatic Breast Cancer Therapies: Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant , PMD-026, DAN-222, Patritumab Deruxtecan, and others
  • Metastatic Breast Cancer Therapeutic Assessment: Metastatic Breast Cancer current marketed and Metastatic Breast Cancer emerging therapies
  • Metastatic Breast Cancer Market Dynamics: Metastatic Breast Cancer market drivers and Metastatic Breast Cancer market barriers 

 

Request for Sample PDF Report for Metastatic Breast Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1

Metastatic Breast Cancer Report Introduction

2

Metastatic Breast Cancer Executive Summary

3

Metastatic Breast Cancer Overview

4

Metastatic Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5

Metastatic Breast Cancer Pipeline Therapeutics

6

Metastatic Breast Cancer Late Stage Products (Phase II/III)

7

Metastatic Breast Cancer Mid Stage Products (Phase II)

8

Metastatic Breast Cancer Early Stage Products (Phase I)

9

Metastatic Breast Cancer Preclinical Stage Products

10

Metastatic Breast Cancer Therapeutics Assessment

11

Metastatic Breast Cancer Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Metastatic Breast Cancer Key Companies

14

Metastatic Breast Cancer Key Products

15

Metastatic Breast Cancer Unmet Needs

16 

Metastatic Breast Cancer Market Drivers and Barriers

17

Metastatic Breast Cancer Future Perspectives and Conclusion

18

Metastatic Breast Cancer Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles

Recent Posts

Osteogenesis Imperfecta Market expected to rise | Companies – Sanofi, Novosteo, Amgen, Mereo BioPharma, Amgen, UCB, Adge Pharmaceuticals, Keros Therapeutics, expected to drive market

Read Full Article